ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)

ArriVent BioPharma shares fell approximately 50%–63% on October 6 after its Phase 3 FURVENT trial of firmonertinib failed to meet its primary endpoint, progression-free survival, in first-line patients with EGFR exon 20 insertion-mutated non-small-cell lung cancer. Shares reached a 52-week low near $12.09; one report cited an intraday low of $11.88. The disclosure came five months after ArriVent filed for an at-the-market offering of up to $250 million, when it described the pivotal Phase 3 program as ongoing. Levi & Korsinsky has opened an investigation into potential securities-law violations; no finding of wrongdoing is reported.

Analysis

The key repricing is the loss of firmonertinib’s pivotal-path value, not the securities-law investigation. For a development-stage biotech, a failed primary endpoint can impair financing leverage as well as the asset’s risk-adjusted value: any next study or indication may require more capital, while issuing equity after a sharp reset would be more dilutive. The May ATM filing is a potential supply/overhang issue, but the article does not establish how much was sold or that prior statements were misleading. The law-firm inquiry is not a finding of misconduct.

In the next few days, expect price discovery to be driven by the full FURVENT dataset and management’s development decision. Over 1–3 months, the important catalysts are endpoint detail, any credible subgroup or secondary-endpoint signal, regulatory feedback, and updated cash/runway and ATM utilization. Over 6–18 months, abandonment or a costly redesign would further weaken the equity case; a defensible path in a subset could preserve option value. Competitors with alternative EGFR exon 20 approaches, including Johnson & Johnson’s Rybrevant franchise, may benefit at the margin if clinicians or trial investigators shift attention, though one failed trial does not establish broad class-level failure.

Contrarian risk: the post-gap price may already discount a near-zero asset, so shorting into extreme volatility has poor asymmetry; residual value depends on data and balance sheet facts not supplied here. Avoid treating the litigation promotion as evidence of liability.

Key Decisions for Investors

• Do not chase a fresh short in AVBP after the gap: borrow availability, squeeze risk, and event volatility can overwhelm the fundamental thesis. Reassess only after the company releases the complete endpoint data and a development plan.
• For existing holders, size exposure as a highly binary residual-asset position; reduce risk if the thesis requires firmonertinib to be the principal value driver and management cannot show a credible next step.
• Set an alert for the full FURVENT readout, cash balance/runway, actual ATM sales, and any FDA interaction. A meaningful subgroup or secondary-endpoint signal plus a funded plan would weaken the bearish thesis; no viable path or materially shorter runway would strengthen it.
• Treat the legal inquiry as a low-confidence, non-trading catalyst unless formal proceedings or specific evidence emerge. The article alone does not establish misleading disclosure.